New antiviral drug will come for COVID, trial continues on humans
An Anti-viral drug named Molnupiravir.
Despite vaccines being effective, we still need medicines to treat COVID-19. Even people taking both doses of the vaccine have a slight risk of contracting the infection and may become moderately or severely ill. There are medicines to treat Kovid-19 but they have to be given in the hospital.
We have a reliable anti-viral drug named Molnupiravir, which is effective in the disease, which is being tested in the final stages of use in humans. Researchers are hoping that it can be used to both treat and prevent infection. Most importantly, it can be taken in pill form. That is, people will not have to be admitted to the hospital to take it. This medicine reduces the potency of SARS-CoV-2 which is the virus responsible for coronavirus. It works by copying one of the building blocks of the virus's genetic material. When the virus reproduces, it makes a new copy of its ribonucleic acid (RNA), and finally, the drug is mixed with it.
So far, a small trial has been conducted on the effect of Molnupiravir in 202 patients of Covid-19. These were patients who started showing symptoms and were not hospitalized. Some of the participants in the trial were given mollupiravir and some were given a placebo. The test results were published as a preprint, meaning they have not yet been formally reviewed by other scientists. The trial showed that after three days of treatment, the infectious SARS-CoV-2 virus was found to be less in people who took 800 mg (2 percent) of mollupiravir than in those who took a placebo (17 percent).
By the fifth day, the virus was not found in those who took either 400 mg or 800 mg of mollupiravir, but the virus was found in up to 11 percent of those who took the placebo. This trial suggests that mollupiravir can kill infectious SARS-CoV-2 in patients with mild symptoms of COVID-19. It can not only in the treatment of corona virus but also reduce the risk of its spread. Now a big trial of this drug is being done with 1,850 people. If it performs well in these trials, its impact could be huge. This antiviral drug can prove to be a valuable weapon in view of falling seriously ill with SARS-CoV-2.